Tradestie Institutional Equity Comparison Engine

ACAD vs CHECU โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ACAD Overall Edge

ACAD Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acadia Pharmaceuticals Inc. (ACAD) driven by superior Valuation, Growth & Margin while CHECU counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, ACAD trades at 15.8x Forward P/E with 10.2% operating margin (+22.8% YoY revenue) versus CHECU at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ACAD sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro) against CHECU sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner ACAD
ACAD 15.8x vs CHECU N/M Fwd P/E
Growth & Margin Winner ACAD
Op Margin 10.2% vs N/A ยท YoY +22.8% vs N/A
Momentum & Technical Winner CHECU
1Y -25.9% vs +3.6% ยท 52W Pos 8% vs 75%
Options & Structure Winner CHECU
BREAKDOWN (6th %ile IV) vs UNCLASSIFIED (N/A IV)
ACAD NASDAQ
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$17.11
-2.73% 1D
Market Cap $3.0B
1M Return -15.76%
1Y Return -25.93%
Forward P/E 15.8x
Unified AI Score
44.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 67.0 Mom 60.0
CHECU NASDAQ
Chenghe Acquisition III Co. Units
Institutional Equity
$10.36
-0.62% 1D
Market Cap N/A
1M Return +2.52%
1Y Return +3.65%
Forward P/E N/M
Unified AI Score
56.2 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ACAD -25.93% CHECU +3.65% Spread: +23.8 pp (CHECU Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ACAD TTM Op. Margin: 10.2% CHECU TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACAD vs CHECU. Trailing 12-month operating profitability (ACAD 10.2% vs CHECU N/A) and valuation multiples (ACAD 15.8x vs CHECU N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ACAD (7) vs CHECU (3)
Institutional Metric ACAD CHECU Criterion Row Winner
Market Capitalization Scale $3.0B N/A Larger Scale ACAD
Trailing P/E Ratio Valuation 8.3x N/M Lower Multiple ACAD
Forward P/E Ratio Valuation 15.8x N/M Lower Multiple ACAD
Revenue Growth (YoY) Growth +22.8% N/A Higher Growth ACAD
Operating Margin (TTM) Profitability 10.2% N/A Higher Margin ACAD
Net Profit Margin Profitability 30.1% N/A Higher Margin ACAD
Return on Equity (ROE) Capital Efficiency 31.4% N/A Higher ROE ACAD
52-Week Range Position Momentum 8% ($16โ€“$31) 75% ($10โ€“$10) Stronger Trend CHECU
Beta / 30D Volatility Risk Regime 0.15ฮฒ ยท 90% Vol N/A Lower Realized Risk CHECU
Unified Institutional Score Composite Signal 44.8 / 100 (HOLD) 56.2 / 100 (HOLD) Higher Composite CHECU

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ACAD vs CHECU Buy Guide
ACAD BREAKDOWN
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live ACAD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CHECU UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CHECU Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ACAD nor CHECU registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.